ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2026
Comparative toxicity and efficacy of consolidative thoracic radiotherapy after first-line chemoimmunotherapy in extensive-stage small-cell lung cancer: real-world retrospective cohort study.
Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundFirst-line chemoimmunotherapy (CT-IT) is the standard treatment for extensive-stage small-cell lung cancer (ES-SCLC), while consolidative thoracic radiotherapy (cTRT) may improve local control and survival. This study evaluated the efficacy and safety of cTRT after first-line CT-IT in patients with ES-SCLC in a real-world setting.
methodsThis retrospective cohort study included 199 patients with ES-SCLC who received first-line CT-IT. Patients were divided into a CT-IT + cTRT group (n = 97) and a CT-IT alone group (n = 102). Survival outcomes included progression-free survival (PFS) and overall survival (OS). Treatment-related adverse events were assessed.
resultsThe two groups were generally comparable at baseline, although the CT-IT + cTRT group had fewer brain metastases and more favorable response-related features after induction treatment. Median PFS and OS were significantly longer in the CT-IT + cTRT group (both P < 0.001). cTRT (P < 0.001) and a longer duration of maintenance immunotherapy (P = 0.031) were independently associated with a better PFS. For OS, cTRT was associated with better survival status (P = 0.003) and liver metastasis with poorer survival status (P = 0.015). Regarding safety, grade 1-2 dermatitis and gastrointestinal toxicity were more frequent in the CT-IT + cTRT group, whereas rates of pneumonitis, esophagitis, immune-related adverse events, and grade 3-4 toxicities were comparable between groups.
conclusionIn this real-world retrospective cohort, the addition of cTRT to first-line CT-IT was associated with significantly improved PFS and OS in patients with ES-SCLC, without an apparent increase in severe treatment-related toxicity. Prospective studies are warranted to confirm these findings and refine patient selection for cTRT.
Indexed as
Identifiers
42862283What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.